Mouse model of colitis-associated colorectal cancer (CAC): Isolation and characterization of mucosal-associated lymphoid cells

Santiago, L. (Universidad de Zaragoza) ; Castro, M. (Universidad de Zaragoza) ; Pardo, J. (Universidad de Zaragoza) ; Arias, M.

Resumen: Colorectal cancer (CRC) is the third most common malignancy worldwide presenting high mortality due to low treatment efficacy. Existing evidence indicates that inflammatory bowel disease (IBD) is associated with a higher risk of developing CRC. Many murine models of inflammation-related colon carcinogenesis (CAC) have been developed to study colon carcinogenesis and novel treatments. A commonly used model involves the combination of a single dose of azoxymethane (AOM), together with three cycles of the inflammatory agent dextran sodium sulfate (DSS) (5 days in drinking water followed by a two-week rest). Following this protocol, around 50% of the animals develop CRCs after 45 days and almost 100% of animals after 60 days. During CAC development, immune cells, cytokines, and other immune mediators are involved in both tumorigenesis and the elimination of cancer cells during immunotherapy. Thus, the study of mucosal immune responses (including lamina propria mononuclear cells and intraepithelial lymphocytes) is important to understand the role of the immune system during development and therapy in CRC. Single immune cell suspensions from lamina propria and epithelium can be purified combining selective tissue digestion and Percoll gradient centrifugation. Isolated cells can be characterized using flow cytometry by analyzing surface antigens or intracellular cytokines and cytotoxic mediators or employed for further investigations like comparative studies of mRNA expression, cell-proliferation assay, protein analysis, or even functional cytotoxicity assays. The CAC model is useful to study the involvement of immune cells not only during the carcinogenesis process but, in addition, during the treatment with novel immunotherapy protocols.

Idioma: Inglés

DOI: 10.1007/978-1-4939-8885-3_13

Año: 2019

Publicado en: Methods in Molecular Biology 1884 (2019), 189-202
ISSN: 1064-3745

Factor impacto SCIMAGO: 0.597 - Molecular Biology (Q3) - Genetics (Q3)

Financiación: info:eu-repo/grantAgreement/ES/MINECO/AEI-010500-2015-161
Financiación: info:eu-repo/grantAgreement/ES/MINECO/SAF2014-54763-C2-1-R

Tipo y forma: Article (PostPrint)

Área (Departamento): Área Fisiología (Dpto. Farmacología y Fisiolog.)
Área (Departamento): Área Inmunología (Dpto. Microb.Med.Pr.,Sal.Públ.)